胃食管腺癌的HER2检测与临床决策:美国病理学家学会、美国临床病理学会和美国临床肿瘤学会指南
该指南由美国病理学家学会、美国临床病理学会和美国临床肿瘤学会专家小组制定,系统综述文献后提出11条推荐,涵盖晚期胃食管腺癌患者HER2检测时机、标本选择、检测算法、评分与报告及临床决策,推荐所有适合HER2靶向治疗的患者在治疗前评估HER2状态,HER2阳性者初始治疗推荐化疗联合HER2靶向药物。
要点
- 所有适合HER2靶向治疗的晚期胃食管腺癌患者,应在开始靶向治疗前评估HER2状态。
- HER2阳性晚期胃食管腺癌患者,初始治疗推荐联合化疗和HER2靶向药物。
- 指南为病理医师提供形态学选择肿瘤组织、检测算法、评分及报告的质量保证指导。
核心结论
- 该指南为晚期胃食管腺癌患者的HER2评估提供了具体推荐,并涉及相关技术问题和结果的临床意义。
研究设计与样本
- 美国病理学家学会、美国临床病理学会和美国临床肿瘤学会召集专家小组,系统综述文献,制定基于证据的指南。
主要发现
- 专家小组提出11条推荐,开放评论参与者对此表示强烈同意。
关键数值与推荐
- 推荐所有适合HER2靶向治疗的晚期胃食管腺癌患者,在开始HER2靶向治疗前应评估肿瘤标本的HER2状态。
- 临床医生应为所有HER2阳性晚期胃食管腺癌患者提供联合化疗和HER2靶向药物作为初始治疗。
- 为病理医师提供关于肿瘤组织形态学选择、检测算法、评分方法、结果解释和报告以及实验室质量保证的指导。
临床怎么用
- 晚期胃食管腺癌患者若为HER2靶向治疗候选者,应在治疗前进行HER2检测。
- HER2阳性晚期胃食管腺癌患者的初始治疗推荐联合化疗和HER2靶向药物。
- 病理医师应按照指南提供的形态学选择、检测算法、评分和报告指导进行操作。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Context ERBB2 (erb-b2 receptor tyrosine kinase 2 or HER2) is currently the only biomarker established for selection of a specific therapy for patients with advanced gastroesophageal adenocarcinoma (GEA). However, there are no comprehensive guidelines for the assessment of HER2 in patients with GEA. Objectives To establish an evidence-based guideline for HER2 testing in patients with GEA, formalize the algorithms for methods to improve the accuracy of HER2 testing while addressing which patients and tumor specimens are appropriate, and to provide guidance on clinical decision making. Design The College of American Pathologists (CAP), American Society for Clinical Pathology (ASCP), and the American Society of Clinical Oncology (ASCO) convened an Expert Panel to conduct a systematic review of the literature to develop an evidence-based guideline with recommendations for optimal HER2 testing in patients with GEA. Results The Panel is proposing 11 recommendations with strong agreement from the open comment participants. Recommendations The Panel recommends that tumor specimen(s) from all patients with advanced GEA, who are candidates for HER2-targeted therapy, should be assessed for HER2 status before the initiation of HER2-targeted therapy. Clinicians should offer combination chemotherapy and an HER2-targeted agent as initial therapy for all patients with HER2-positive advanced GEA. For pathologists, guidance is provided for morphologic selection of neoplastic tissue, testing algorithms, scoring methods, interpretation and reporting of results, and laboratory quality assurance. Conclusion This guideline provides specific recommendations for assessment of HER2 in patients with advanced GEA while addressing pertinent technical issues and clinical implications of the results.
引用
- Bartley AN, Washington MK, Colasacco C, et al. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. J Clin Oncol. 2016. PMID: 28129524. doi:10.1200/JCO.2016.69.4836
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。